AnaptysBio (NASDAQ:ANAB) Earns Neutral Rating from HC Wainwright

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $22.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 31.34% from the stock’s current price. […]

Leave a Reply

Your email address will not be published.

Previous post Barclays Forecasts Strong Price Appreciation for Hawaiian Electric Industries (NYSE:HE) Stock
Next post Canaan (NASDAQ:CAN) Earns “Buy” Rating from Rosenblatt Securities